168 related articles for article (PubMed ID: 25399222)
1. Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.
Bashier AM; Abdelgadir EI; Khalifa AA; Rashid F; Abuelkeir SM; Bachet FE
Saudi Med J; 2014 Nov; 35(11):1404-7. PubMed ID: 25399222
[TBL] [Abstract][Full Text] [Related]
2. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
4. [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
Sierra Poyatos R; Riobó Serván P; Vázquez Martínez C
Nutr Hosp; 2014 Oct; 31(1):292-8. PubMed ID: 25561121
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
[TBL] [Abstract][Full Text] [Related]
7. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
8. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
9. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.
Chiquette E; Toth PP; Ramirez G; Cobble M; Chilton R
Vasc Health Risk Manag; 2012; 8():621-9. PubMed ID: 23166441
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
[TBL] [Abstract][Full Text] [Related]
11. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
[TBL] [Abstract][Full Text] [Related]
12. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
[TBL] [Abstract][Full Text] [Related]
13. [The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].
Roubícek T; Mráz M; Bártlová M; Kaválková P; Haluzíková D; Trachta P; Housová J; Matoulek M; Svacina S; Haluzík M
Vnitr Lek; 2010 Jan; 56(1):15-20. PubMed ID: 20184107
[TBL] [Abstract][Full Text] [Related]
14. Effects of exenatide in poorly controlled type 2 diabetes.
Kaimal N; Schofield J; Zaki A; Patel R; Sharma M; McCourt E; Imtiaz KE
QJM; 2012 Apr; 105(4):321-6. PubMed ID: 22056400
[TBL] [Abstract][Full Text] [Related]
15. Determining predictors of response to exenatide in type 2 diabetes.
Anderson SL; Trujillo JM; McDermott M; Saseen JJ
J Am Pharm Assoc (2003); 2012; 52(4):466-71. PubMed ID: 22825226
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
17. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
Paul S; Best J; Klein K; Han J; Maggs D
Diabetes Obes Metab; 2012 Sep; 14(9):826-34. PubMed ID: 22510305
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE; Maggs D; Nielsen LL; Stonehouse AH; Poon T; Zhang B; Bicsak TA; Brodows RG; Kim DD
Diabetes Obes Metab; 2006 Jul; 8(4):419-28. PubMed ID: 16776749
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
Hwang YC; Kim A; Jo E; Yang Y; Cho JH; Lee BW
BMC Endocr Disord; 2017 Oct; 17(1):68. PubMed ID: 29065865
[TBL] [Abstract][Full Text] [Related]
20. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
